Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 apixaban after recent acute coronary syndrome
NL-OMON33485Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute coronary syndrome (ACS) and coronary arteriosclerosis comparing Apixaban plus standard care with Placebo plus standard care (2 arms). Started Sep 2009; status: active, not recruiting.
02
Drugs
apixaban
03
Conditions
acute coronary syndrome (ACS)coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON33485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33485.